$14.9M capital deployed

28% primary ownership

Sep '11 initial capital deployed

return to top

Why Putney?

Headquartered in Portland, ME, Putney is a rapidly growing pet pharmaceutical company focused on developing high-quality, generic prescription medicines for pets.

Putney’s mission is to provide veterinary practices with FDA-approved veterinary generic medicines that meet pet medical needs and offer cost-effective alternatives for pet owners.

According to IMS Health, 86% of all human prescriptions in the U.S. are filled with a generic, yet very few generics exist for drugs prescribed for pets. Analysis of FDA Center for Veterinary Medicine approvals reveals that 91% of FDA-approved drugs for pets have no generic equivalent. The overall size of the pet pharmaceutical market is significant. Packaged Facts, in its April 2014 report entitled, “Pet Medications in the U.S.,” stated that U.S. retail sales of pet medications reached $8 billion in 2013 and projected that the market will grow to more than $10 billion in 2018, reflecting a compound annual growth rate of 5%.

During the second quarter of 2015, Putney continued to grow its portfolio of FDA-approved, high-quality generic medicines for pets, launching Tiletamine-Zolazepam, the only FDA-approved generic equivalent of Zoetis’ Telazol®. Tiletamine-Zolazepam is Putney’s fifth first-to-market veterinary generic and its sixth new product in the past seven months. Putney’s product portfolio now totals 10 generic equivalents of companion animal veterinary drugs. New product launches and growth in the base business are continuing to drive revenue increases at Putney.

(Updated as of 06/30/15)